Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Non-Deal Roadshow (November 2019)

42 slides from Fresenius SE & Co. KGaA's roadshow presentation, Nov 7, 2019

  1. Slide 1: Roadshow Tel Aviv

    Roadshow Tel Aviv Tel Aviv, 07 November 2019 Frankfurt stock exchange: FRE │ US ADR program: FSNUY │ www.fresenius.com/investors

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: A Global Leader In Health Care Products And Services

    A Global Leader In Health Care Products And Services ~€33.5 bn in Sales Global presence in (as of Dec. 31, 2018) 100+ countries Total Shareholder Return: 10-year CAGR: ~15% Strong portfolio 292,000+ employees of products (30% of sales) worldwide and services (70% of sales) (as of September 30, 2019)

  4. Slide 4: Strong and Balanced Health Care Portfolio

    Strong and Balanced Health Care Portfolio Ownership: ~31% Ownership: 100% Ownership: 100% Ownership: 77% Dialysis Products Hospital Supplies Hospital Operation Projects and Services for Health Care Services Hospitals • Dialysis services • IV drugs • Acute care • Post-acute care • Hemodialysis produc

  5. Slide 5: Total Shareholder Return – CAGR, Rounded

    Total Shareholder Return – CAGR, Rounded 10 years 15 years 20 years 15% 14% 13% 12% 10% 9% 8% 8% 7% 6% 6% 4% DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 Fresenius MSCI World Fresenius DAX S&P 500 MSCI World Fresenius Fresenius Health Care Health Care Health Care Source: Bloomberg; dividen

  6. Slide 6: Fresenius Medical Care: Global Dialysis Market Leader

    Fresenius Medical Care: Global Dialysis Market Leader • The world’s leading provider of dialysis products Market Dynamics and services treating more than 342,000 patients1 in 4,003 clinics1 Global Dialysis Market 2018: • Provide highest standard of product quality and • ~€71 bn • ~6% patient growth

  7. Slide 7: Fresenius Kabi: A Leading Global Hospital Supplier

    Fresenius Kabi: A Leading Global Hospital Supplier • Comprehensive product portfolio for critically and Market Dynamics chronically ill patients • Strong Emerging Markets presence Global Addressable Market 2018: • Leading market positions in four product • ~€81 bn segments Growth Drivers: Generic IV

  8. Slide 8: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Germany

    Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Germany • ~5%1 share in German acute care hospital Market Dynamics market • Organic growth based on growing number of German Acute Care Hospital Market: admissions and reimbursement rate increases • ~€102 bn2 • Ranks as quality lead

  9. Slide 9: Fresenius Helios: Europe's Largest Private Hospital Operator Helios Spain

    Fresenius Helios: Europe’s Largest Private Hospital Operator Helios Spain • ~€3.0 bn sales in 2018 Market Dynamics • ~12%1 share in Spanish private hospital market Spanish Private Hospital Market: • Market leader in size and quality with excellent • ~€14 bn2 growth prospects Growth Drivers: • Broad

  10. Slide 10: Fresenius Vamed: Leading Global Hospital Projects and Services Specialist

    Fresenius Vamed: Leading Global Hospital Projects and Services Specialist • Manages hospital construction/expansion Market Dynamics projects and provides services for health care facilities worldwide Growth Drivers: • Offers project development, planning, turnkey • Emerging Market demand for buildin

  11. Slide 11: Fresenius Group: Capital deployment centers on sustainable long-term value creation

    Fresenius Group: Capital deployment centers on sustainable long-term value creation Re-investments in Fuel organic growth with low-risk high- own business return investments Short-term focus on small bolt-on Strategic acquisitions; long-term rigorous pursuit of acquisitions inorganic growth trajecto

  12. Slide 12: Fresenius Group: Healthy Growth Targets 2020 - 2023

    Fresenius Group: Healthy Growth Targets 2020 - 2023 Growing Markets with High Marketing of existing Attractive markets Entry Barriers value chain Strengthening and Attractive Product Pipeline Market consolidation extension of value chain Entry into attractive Development of post- Synergies biosimila

  13. Slide 13: Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs)

    Fresenius Group: Healthy Growth Targets 2020 – 2023 (CAGRs) Organic sales growth 4 – 7% (plus ~1% small to mid- size acquisitions) Organic net income1 growth 5 – 9% (plus ~1% small to mid- size acquisitions) 1 Net income attributable to shareholders of Fresenius SE & Co. KGaA Before special items Ro

  14. Slide 14: Financial Review Q3/19

    Financial Review Q3/19 Roadshow Tel Aviv, 07 November 2019 © Fresenius SE & Co. KGaA Investor Relations 14

  15. Slide 15: Q3/19 Highlights

    Q3/19 Highlights • Strong organic sales growth across all business segments • Growth investments proceeding according to plan • Fresenius Kabi: excellent growth in Emerging Markets partially offsets softer development in North America • Fresenius Helios showing excellent organic sales growth across

  16. Slide 16: Fresenius Kabi: Update

    Fresenius Kabi: Update North America • Increased competition for certain molecules • The opioid market has not recovered as anticipated • 31 Kabi-marketed IV drugs currently designated in shortage (vs. 36 at Q2/19) • Low to mid-single-digit price erosion in our base product portfolio • Product launc

  17. Slide 17: Fresenius Helios: Update

    Fresenius Helios: Update Helios Germany Investment initiatives • Employer of choice: Continued to attract meaningful number of nurses in Q3/19 • Vacant chief doctor positions now re-filled • Good progress with transformation of MVZs (“outpatient centers”) within new business line Outpatient Services

  18. Slide 18: Fresenius Helios: Update

    Fresenius Helios: Update Helios Spain Expansion in Spain Expansion in Latin America • Opening of two new outpatient centers in • Acquisition of two additional hospitals the cities of Toledo and Algeciras in Colombia • Acquisition of plot in the metropolitan • ~€50 million of sales area of Barcelona

  19. Slide 19: Fresenius Group: Q3/19 Key Financials

    Fresenius Group: Q3/19 Key Financials €m Q3/191 IFRS 16 special Q3/19 ∆ YoY cc1,2 effect items reported Sales 8,877 -35 - 8,842 6% EBIT 1,130 23 -24 1,129 -1% Net interest -124 -47 -1 -172 15% Income taxes -232 5 25 -202 -10% Net income3 453 -8 -1 444 0% Balance sheet total 61,092 5,667 - 66,759 Ope

  20. Slide 20: Fresenius Group: Q3/19 Business Segment Growth

    Fresenius Group: Q3/19 Business Segment Growth Organic sales growth1 EBIT growth (cc)1 +5% -3% +5% +1% +6% -10% +17% +10% +5% -1% 1 On a comparable basis: Q3/18 adjusted for divestitures of Care Coordination activities at FMC; Q3/19 adjusted for IFRS 16 effect. All figures before special items Roads

  21. Slide 21: Fresenius Kabi: Q3/19 Regional Highlights (1/2)

    Fresenius Kabi: Q3/19 Regional Highlights (1/2) North America Europe • -4% organic growth • 4% organic growth • Increasingly intense competitive • Strong growth of enteral nutrition environment for certain molecules business • Further easing of shortage tailwinds • Confirm FY/19 outlook: Low to mid-

  22. Slide 22: Fresenius Kabi: Q3/19 Regional Highlights (2/2)

    Fresenius Kabi: Q3/19 Regional Highlights (2/2) Emerging Markets China: • 18% organic sales growth • Continued positive momentum Asia-Pacific ex China: • 19% organic sales growth Latin America/Africa: Total Emerging Markets • 16% organic sales growth Confirm FY/19 outlook: Clearly double-digit organ

  23. Slide 23: Fresenius Kabi: Q3 & Q1-3/19 EBIT Growth

    Fresenius Kabi: Q3 & Q1-3/19 EBIT Growth €m Q3/19 ∆ YoY cc Q1-3/19 ∆ YoY cc North America 225 -8% 703 -2% Margin 36.3% -180 bps 38.7% 20 bps Europe 75 -11% 241 -6% Margin 13.3% -230 bps 14.1% -150 bps Asia-Pacific/Latin 135 34% 352 24% America/Africa Margin 23.4% 330 bps 21.6% 200 bps Corporate and

  24. Slide 24: Fresenius Helios: Q3/19 Highlights

    Fresenius Helios: Q3/19 Highlights Helios Germany Helios Spain • Strong organic sales growth of 5%; positive • Healthy organic sales growth of 9%; admissions development decline in admissions during hot summer months not as pronounced as in prior year • Sales growth supported by reclassification of

  25. Slide 25: Fresenius Helios: Q3 & Q1-3/19 Key Financials

    Fresenius Helios: Q3 & Q1-3/19 Key Financials €m Q3/19 ∆ YoY Q1-3/19 ∆ YoY Total sales 2,230 7% 6,890 2%/5%1 Thereof Helios Germany 1,474 5% 4,465 -1%/4%1 Thereof Helios Spain 757 12% 2,425 9% Total EBIT2 183 -10% 723 -7%/-5%1 Margin 8.2% -160 bps 10.5% -100 bps Thereof Helios Germany 130 -9% 433 -1

  26. Slide 26: Fresenius Vamed

    Fresenius Vamed • Strong Q3/19 with 17% organic sales €m Q3/19 ∆ YoY Q1-3/19 ∆ YoY growth Total sales 562 18% 1,469 48% • Both, service business and project Thereof organic sales 17% 24%1 business contributed to strong growth in Q3/19 Service business 349 11% 1,025 60% 29%1 Project business 213 32%

  27. Slide 27: Fresenius Group: Cash Flow

    Fresenius Group: Cash Flow Operating CF1 Capex (net) Free Cash Flow1,2 €m Q3/19 LTM Margin Q3/19 LTM Margin Q3/19 LTM Margin 362 13.4% -179 -10.0% 183 3.4% 183 7.0% -90 -4.7% 93 2.3%3 27 3.2% -10 -1.6% 17 1.6% Corporate/Other 11 n.a. -13 n.a. -2 n.a. Excl. FMC 583 9.5%4 -292 -6.9% 291 2.6%4 1,298 10

  28. Slide 28: Fresenius Group: 2019 Financial Outlook by Business Segment

    Fresenius Group: 2019 Financial Outlook by Business Segment FY/18 Q1-3/19 FY/191 €m (except otherwise stated) Base Actual1 FY/19e1 New Sales growth (org) 6,544 4% 3% - 6% EBIT growth (cc) 1,1392 4% 3% - 6% Sales growth (org) 8,993 5% 2% - 5% EBIT growth 1,052 -7% -5% to -2% Sales growth (org) 1,688

  29. Slide 29: Fresenius Group: 2019 Financial Guidance

    Fresenius Group: 2019 Financial Guidance €m FY/18 Q1-3/19 FY/19e2 (except otherwise stated) Base1 Actual2 FY/19e2 New Sales growth 33,009 6% 4% - 7% (cc) Net income3 1,872 0% ~0% growth (cc) 1 Before special items and after adjustments 2 Excluding transaction-related expenses, revaluations of biosim

  30. Slide 30: Attachments

    Attachments Roadshow Tel Aviv, 07 November 2019 © Fresenius SE & Co. KGaA Investor Relations 30

  31. Slide 31: Fresenius Group: Leverage Ratio

    Fresenius Group: Leverage Ratio Net Debt/EBITDA target 2019 4,00 4.0 Around the upper-end of self-imposed target 3.5 3,50 corridor of 2.5 – 3.0 x3 2 3.22 3.21 2 2 3.13 3.09 2.98 3,00 3.0 2.84 2.80 2.75 2.67 2.71 2.65 2.55 2.53 2,50 2.5 2.33 2,00 1 2011 2012 2013 2014 2015 2016 2017 Q1 Q2 Q3 Q4 Q1 Q2

  32. Slide 32: Fresenius Kabi: Organic Sales Growth by Regions

    Fresenius Kabi: Organic Sales Growth by Regions ∆ YoY ∆ YoY €m Q3/19 organic Q1-3/19 organic North America 619 -4% 1,815 -3% Europe 564 4% 1,709 3% Asia-Pacific/Latin 578 17% 1,629 15% America/Africa Asia-Pacific 406 18% 1,121 15% Latin America/Africa 172 16% 508 16% Total sales 1,761 5% 5,153 4% Ro

  33. Slide 33: Fresenius Kabi: Organic Sales Growth by Product Segment

    Fresenius Kabi: Organic Sales Growth by Product Segment ∆ YoY ∆ YoY €m Q3/19 organic Q1-3/19 organic IV Drugs 746 -2% 2,202 -1% Infusion Therapy 208 7% 621 3% Clinical Nutrition 492 10% 1,416 9% Medical Devices/ 315 14% 914 11% Transfusion Technology Total sales 1,761 5% 5,153 4% Roadshow Tel Aviv,

  34. Slide 34: Fresenius Helios: Key Metrics

    Fresenius Helios: Key Metrics Q1-3/19 FY/18 ∆ No. of hospitals Helios Germany 86 86 0% - Acute care hospitals 83 83 0% No. of hospitals Helios Spain 50 47 6% (Hospitals) No. of beds Helios Germany 28,934 29,329 -1% - Acute care hospitals 28,407 28,802 -1% No. of beds Helios Spain 7,126 7,019 2% (Hos

  35. Slide 35: Attachments

    Attachments Roadshow Tel Aviv, 07 November 2019 © Fresenius SE & Co. KGaA Investor Relations 35

  36. Slide 36: FY/18 base for Fresenius Group Guidance FY/19

    FY/18 base for Fresenius Group Guidance FY/19 €m Sales reported 33,530 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 33,009 Net income reported 2,027 Transaction Costs, Akorn, Biosimilars 25 Bridge Financing Costs Akorn 12 Revaluations of Biosimilars c

  37. Slide 37: FY/18 base for Fresenius Medical Care Outlook FY/19

    FY/18 base for Fresenius Medical Care Outlook FY/19 €m Sales reported 16,547 Divestitures of Care Coordination activities at FMC (H1/18) -521 Sales basis for growth rates 16,026 Net income reported 1,982 Impact of FCPA related charge 28 Gain related to divestitures of Care Coordination activities -6

  38. Slide 38: FY/18 base for Fresenius Kabi Outlook FY/19

    FY/18 base for Fresenius Kabi Outlook FY/19 €m Sales basis for growth rates 6,544 Transaction Costs Akorn, Biosimilars 34 Revaluations of Biosimilars contingent liabililties 7 EBIT (before special items = base for Kabi guidance) 1,139 The special items are reported in the Group Corporate/Other segme

  39. Slide 39: IFRS 16: Profit and Loss - Implications

    IFRS 16: Profit and Loss - Implications €m Expected IFRS 16 effect on 2019 Sales - ~€0.1 bn (discontinuation of sale-leaseback transactions at FMC NA) EBITDA + ~€1.0 bn (fewer rent expenses) Depreciation and amortization - ~€0.9 bn (additional depreciation) EBIT + ~€0.1 bn Interest - ~€0.2 bn (addit

  40. Slide 40: IFRS 16: Balance Sheet

    IFRS 16: Balance Sheet €m Expected IFRS 16 effect on 2019 Right-of-use-asset ~€5.2 bn Lease liability ~€5.5 bn Equity ~-€0.3 bn Leverage + ~30-40 bps Leases have to be recognized as a right-of-use-asset and corresponding liability Roadshow Tel Aviv, 07 November 2019 © Fresenius SE & Co. KGaA Investo

  41. Slide 41: 26th Consecutive Dividend Increase

    Fresenius Group: 26th Consecutive Dividend Increase CAGR +16% 0.75 0.80 0.62 0.55 0.32 0.37 0.42 0.44 € 0.29 0.23 0.25 0.22 0.19 0.16 0.02 '93 '05 '06 '07 '08 '09 '10 '11 '12 '13 '14 '15 '16 '17 '18 Dividend growth aligned to EPS growth Pay-out ratio: 24% Roadshow Tel Aviv, 07 November 2019 © Fresen

  42. Slide 42: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar 20 February 2020 Results FY/19 06 May 2020 Results Q1/20 20 May 2020 Annual General Meeting 30 July 2020 Results Q2/20 29 October 2020 Results Q3/20 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co.

Fresenius SE & Co. KGaA — Non-Deal Roadshow (November 2019) on 6ix